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The ubiquitin-proteasome system controls the turnover of regulatory proteins involved in critical cellular processes including cell cycle progression, cell development and differentiation, apoptosis, angiogenesis and cell signaling pathways [1] [2] . This system requires the action of three enzymes: E1 ubiquitin activating enzyme, E2 ubiquitin conjugating enzyme and E3 ubiquitin ligase 3 . Firstly, the ubiquitin is activated by the E1 activating enzyme and once it is activated, it is then transferred to E2 conjugating enzyme. The final step is the formation of an iso-peptide bond between a lysine of the target protein and the C-terminal glycine of ubiquitin (carried by E2). This step usually requires the action of an E3 ubiquitin ligase 4 .
Interference with the proteasome activity was proven to be effective in cancer therapeutics since the clinical approval of bortezomib (Velcade®) as a proteasome inhibitor for treatment of relapsed multiple myeloma and mantle cell lymphoma 5 . However, the requirement for more specific inhibiting targets like the design of potential E2 or E3 inhibitors, has appeared in order to reduce the side effects resulting from bortezomib 6 . Recently, many E1 and E3 ligase inhibitors such as PYR-41, Nutlin-3a,
P013222 and SCF-I2 have been successful and progressed to preclinical/clinical development. Also, the approved myeloma drug thalidomide has been recently identified as an E3 ligase inhibitor 7 .
Among the E2 ubiquitin conjugating enzyme family, Rad6B is of special interest since it is found to be over-expressed in many human cancer cell lines and tumors [8] [9] . Constitutive over-expression of Rad6B in the non-transformed human breast epithelial cell line MCF 10A induces a number of adverse effects associated with cancer progression such as formation of multinucleated cells, centrosome amplification, abnormal mitosis, aneuploidy, and transformation 10 . Most importantly, Rad6B has been shown to positively regulate β-catenin stabilization and activity that drives the malignant progression of breast cancer cells [11] [12] [13] . Since β- [14] [15] [16] [17] . Rad18/Rad6 ubiquitin ligase complex is also important in the activation of the Fanconi anemia tumor suppressor pathway, which plays critical roles in genome integrity and tumor resistance to a variety of chemotherapeutic agents, including those that induce DNA crosslinks and DNA double strand breaks [17] [18] . Rad6 has also been shown to associate with RNF168 to monoubiquitinate histone H1.2 thereby enabling chromatin relaxation and allowing DNA damage response factors access to damage sites 19 . Moreover, increased expression or activation of these DNA damage response (DDR) signaling and repair genes accounts for tumor resistance to chemotherapy 9, [20] [21] [22] . Therefore, development of DNA damage response and repair signal inhibitors are important to effectively treat these tumors.
We have recently reported [4-amino-6-(arylamino)-1,3,5-triazin-2-yl]methyl 4-nitrobenzoates TZ8-TZ9 ( Fig. 1 ) as novel and selective Rad6B-inhibitory lead compounds 23 . These inhibitors were identified by virtual screening of a pharmacophore model generated from the conserved key residues stabilizing the E2-ubiquitin thioester intermediate against a
pre-prepared database using drug-like filters which determined the substituted diamino-triazine core structure as a starting point for analogue synthesis. Triazine analogue synthesis coupled to in vitro anticancer evaluation led to the identification of lead compounds TZ8-TZ9 23 . Asn119/Gln93 and between the phenyl (hydrazide) ring and Leu89 were also apparent from our docking analysis. The importance of these active site residues to the allosteric effect on Rad6B induced by E3 ligases, and the observation that no other E2 family members (with the exception of Rad6A) have residues corresponding to Gln93 or Asn119, suggest that these triazinecarbohydrazides could be selective Rad6B inhibitors 24 . The synthesis of the 4-amino-6-(arylamino)-1,3,5-triazine-2 carbohydrazide (3a-e) was accomplished in two steps from arylbiguanide hydrochloride salts (1a-e), which were prepared from commercially available substituted aniline and dicyandiamide according to previously reported procedures [25] [26] . Neutralization of the arylbiguanide hydrochloride salt using sodium methoxide/methanol was followed by reaction with dimethyloxalate in refluxing methanol. This gave the intermediate methyl 
3a-e
Scheme.1: Synthetic pathway for compounds 3a-e A similar strategy was used to synthesize the N'-phenyl-4,6-bis(arylamino)-1,3,5-triazine-2-carbohydrazides (6a-e) from bisarylbiguanide hydrochloride salts (4a-e), which were prepared from commercially available substituted aniline and sodium dicyanamide according to previously reported procedures [25] [26] . Neutralization of the bisarylbiguanide hydrochloride salt using sodium methoxide/methanol was followed by reaction with dimethyloxalate in refluxing methanol. This Table 1 : IC50 Values for New Triazine Analogues.
As described in the methods, the MTS assay was used to evaluate cell survival in the In these assays ( Fig. 4A and 4B) , ubiquitin conjugation to Rad6 enzyme readily occurs in the positive control (lane 3 in Fig. 4A and lane 2 in Fig.   5A ), but not in the negative controls, which lacks either Rad6 (lane 1 in To further assess their inhibitory effects on Rad6B ability to transfer ubiquitin to the substrate, in vitro ubiquitination assays were performed using H2A as substrate 23 . We have selected four compounds 6a, b, c, e that exhibited more favorable IC 50 values and better inhibitory effects on Rad6 conjugation to ubiquitin in the in vitro ubiquitin assays compared to TZ9. As shown in Figure 5A and 5B, compounds 6a, b, c, e exhibited superior Rad6B inhibitory properties, both in its conjugation to ubiquitin and substrate ubiquitination (H2A-Ub) when compared to TZ9. Together, these studies report the synthesis of new triazines with better Rad6B inhibitory activities and anticancer properties compared to previously reported Rad6B inhibitor TZ9 in in vitro evaluations. Moreover, when compared to TZ9 in in vitro ubiquitin conjugation assays, compounds 6a, b, c, e exhibited superior Rad6B inhibitory properties, both in its conjugation to ubiquitin and to the substrate H2A.
